Epstein Secrets

CEO Emily Reichert, and Information and Technology Foundation Senior Fellow David Hart; 1:00 PM Visitors: • No visitors scheduled. This Town: • Brookings online discussion on the defense industrial base - 'The defense industrial base and the future of warfare' Brookings Institution Foreign Policy prog

e AP (10/22, Marchione) reports that the "antiviral medicine given to hospitalized patients through an IV," being marketed by manufacturer Gilead as Veklury, "cut the time to recovery by five days - from 15 days to 10 on average - in a large study led by the U.S. National Institutes of Health." The drug

CEO Emily Reichert, and Information and Technology Foundation Senior Fellow David Hart; 1:00 PM Visitors: * No visitors scheduled. This Town: * Brookings online discussion on the defense industrial base — `The defense industrial base and the future of warfare' Brookings Institution Foreign Policy prog

63> (10/22, Marchione) reports that the "antiviral medicine given to hospitalized patients through an IV," being marketed by manufacturer Gilead as Veklury, "cut the time to recovery by five days - from 15 days to 10 on average — in a large study led by the U.S. National Institutes of Health." The drug

CEO Emily Reichert, and Information and Technology Foundation Senior Fellow David Hart; 1:00 PM Visitors: • No visitors scheduled. This Town: • Brookings online discussion on the defense industrial base - 'The defense industrial base and the future of warfare' Brookings Institution Foreign Policy prog

e AP (10/22, Marchione) reports that the "antiviral medicine given to hospitalized patients through an IV," being marketed by manufacturer Gilead as Veklury, "cut the time to recovery by five days - from 15 days to 10 on average - in a large study led by the U.S. National Institutes of Health." The drug